India's New IPR Policy: Balanced And Evolving?
This article was originally published in SRA
Executive Summary
India's new national intellectual property rights (IPR) policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".